Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -185.36M | -157.32M | -137.95M | -121.52M | -102.67M |
| Total Depreciation and Amortization | 155.00K | 130.00K | 105.00K | 77.00K | 68.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.13M | 19.08M | 16.20M | 14.09M | 12.30M |
| Change in Net Operating Assets | 26.23M | 21.87M | 14.81M | -5.63M | -10.65M |
| Cash from Operations | -134.85M | -116.24M | -106.83M | -112.98M | -100.96M |
| Capital Expenditure | -400.00K | -340.00K | -280.00K | -82.00K | -48.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -402.10M | -217.17M | -318.17M | -236.08M | -- |
| Cash from Investing | -402.50M | -217.51M | -318.45M | -236.16M | -48.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 197.34M | 195.15M | 32.26M | 1.03M | 334.13M |
| Repurchase of Common Stock | -- | -- | -- | -975.00K | -975.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 596.00K |
| Cash from Financing | 197.34M | 195.15M | 32.26M | 56.00K | 333.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -340.01M | -138.60M | -393.03M | -349.09M | 232.75M |